Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EPRX · NASDAQ · Pharmaceutical Preparations · Foreign private issuer
Eupraxia Pharmaceuticals (EPRX) · oqro.io/stocks/EPRX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Eupraxia Pharmaceuticals is on record in SEC filings since 2006.
No open-market sale by an insider of Eupraxia Pharmaceuticals (EPRX) was filed with the SEC in the last 90 days.
No trade in Eupraxia Pharmaceuticals (EPRX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$5.80−0.32 (−5.23%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−6.6% (−$0.41) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $6.21 on Nov 20, 2025 to $5.80 on Nov 20, 2026 (−6.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Vancouver. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−6.6%
Market value
–
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6.25M shares sold short, −4.5% vs the previous count, 10.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$0
Year ended Dec 31, 2025
Net income, fiscal 2025
−$38.6M
A loss for the year
Shares outstanding
Not available
Reported per share class only, with no single total
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on EPRX over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in eosinophilic esophagitis. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 18, 2025, EPRX is down 8.9% and the index fund is up 4.5%: 13 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EPRX moves
Beta 1.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Off-exchange trading: 44.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (28.3% on ATS, 16.0% with other brokers), below its 26-week average of 46.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (17.9%), INTELLIGENT CROSS LLC (11.2%), SIGMA X2 (10.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
On the public record for Eupraxia Pharmaceuticals over the 12 months to Nov 21, 2026: 1 clinical trial.